Join the club for FREE to access the whole archive and other member benefits.

Elevian has secured $40 million for anti-aging diseases and heart stroke

17-Sep-2021

Key points from article :

The biotech raised $40 million to bankroll studies based on research that emerged from Harvard in the early 2010s, into clinics. (American Heart Association)

The Series A proceeds will fund phase 1 trials for Elevian's lead program in stroke recovery, slated to begin in early 2023, said co-founder Mark Allen.

Elevian's core program focuses on the growth differentiation factor 11, or GDF11, a protein that restores the body's natural regenerative capacity. 

"While the molecule appears to have very broad regenerative effects and anti-aging effects, there's no regulatory path for aging", Allen added.

Elevian's lead asset hopes to improve the healing response in patients who have had strokes. 

Preclinical data on GDF11 treatments show improved recovery after stroke via enhanced vascular repair, reduced inflammation and sparking formation of new neurons in the brain, Elevian said. 

$40 million for clinical research, lead program-stroke recovery focuses GDF11

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Institute

Non-profit US organization that funds cardiovascular medical research

Company

Young blood medicine maker for body rejuvenation.

Company Representative

Co-Founder and CEO at Elevian